← All trials
NCT05959616
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2024
- Primary completion
- Dec 30, 2025
- Completion date
- Nov 30, 2026
- First posted
- Jul 25, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 70
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OxfordLead sponsor
- Johns Hopkins UniversityCollaborator
- Wellcome TrustCollaborator
- United States NavyCollaborator
- PATHCollaborator
- United States ArmyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.